
This commentary discusses the most significant advances that were presented at the 12th Annual Meeting of the American Society of Gene Therapy. Many reports focused on clinical trials for the treatment of cancer and other pathological conditions, preclinical studies for various diseases, genetic immunization protocols and improvement of vector design. In this respect, a major emphasis was placed on safety issues.

